文献速递心血管MR

心肌肌球蛋白抑制剂对梗阻性肥厚型心肌病心脏结构与纤维化的CMR荟萃分析

Effect of cardiac myosin inhibitors on cardiac structure and myocardial fibrosis in obstructive hypertrophic cardiomyopathy: a meta-analysis of cardiac magnetic resonance outcomes.
PubMed 文献 · Clin Radiol · 2026-06-18

本荟萃分析纳入3项随机对照试验共150例梗阻性肥厚型心肌病患者,评估心肌肌球蛋白抑制剂对心脏磁共振结局的影响。结果显示治疗可降低左心室质量指数、最大左心室壁厚度及左心房容积指数。对晚期钆增强和细胞外容积分数未显示显著改善。

要点

  • 心肌肌球蛋白抑制剂可改善梗阻性肥厚型心肌病心脏结构参数
  • 对心肌纤维化相关CMR指标未显示显著改善
  • CMR可用于监测此类治疗的结构重塑效果

核心结论

  • 心肌肌球蛋白抑制剂对梗阻性肥厚型心肌病的心脏结构有改善作用,但对心肌纤维化的影响尚不明确。

研究设计与样本

  • 荟萃分析检索PubMed、Cochrane Library和Embase数据库,时间截至2025年7月27日。
  • 纳入3项随机对照试验,共150例梗阻性肥厚型心肌病患者。
  • 使用随机效应模型汇总平均差及95%置信区间,结局同时纳入mavacamten和aficamten。

关键影像表现/征象

  • 与安慰剂相比,心肌肌球蛋白抑制剂治疗可降低左心室质量指数、最大左心室壁厚度和左心房容积指数。
  • 晚期钆增强比例与细胞外容积分数在治疗组与安慰剂组间未见显著差异。

诊断标准与关键数值

  • 左心室质量指数平均差-20.01 g/m²,95%CI -29.77至-10.26,P<0.0001,I²=67.7%。
  • 最大左心室壁厚度平均差-2.66 mm,95%CI -3.53至-1.79,P<0.0001,I²=40.6%。
  • 左心房容积指数平均差-13.02 mL/m²,95%CI -17.17至-8.87,P<0.0001,I²=15.6%。
  • 晚期钆增强平均差0.54%,95%CI -0.48至1.56,P=0.2973,I²=0%。
  • 细胞外容积分数平均差1.43%,95%CI -0.02至2.88,P=0.0528,I²=0%。

临床应用与阅片要点

  • CMR可用于监测心肌肌球蛋白抑制剂治疗梗阻性肥厚型心肌病后的左心室质量指数、最大壁厚度和左心房容积指数变化。
  • 晚期钆增强和细胞外容积分数作为心肌纤维化指标在该治疗中未显示显著变化,解读时需结合临床背景。

局限性

  • 纳入研究数量仅3项,总样本量150例。
  • 左心室质量指数汇总结果异质性较高,I²为67.7%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: Recent advancements have introduced cardiac myosin inhibitors (CMIs) that have demonstrated significant efficacy in obstructive hypertrophic cardiomyopathy (oHCM). This meta-analysis aims to synthesize the current understanding of the impact of CMIs on cardiac magnetic resonance (CMR) findings in patients with oHCM.

MATERIAL AND METHODS: A search of the PubMed, Cochrane Library, and Embase databases was conducted from their inception until July 27, 2025. Random-effects models were used to pool mean differences with 95% confidence intervals. Both mavacamten and aficamten were included in all outcomes.

RESULTS: Three randomised controlled trails (RCTs) involving 150 patients were included in this meta-analysis. This meta-analysis demonstrates a reduction in left ventricular mass index with CMIs compared to the placebo group (mean differences [MD]: -20.01 g/m2, 95% confidence interval [CI]: -29.77 to -10.26, P<0.0001, I2 = 67.7%). And CMIs can also reduce maximal left ventricular wall thickness (MD: -2.66 mm, 95% CI: -3.53 to -1.79, P<0.0001, I2 = 40.6%). Meanwhile, the pooled results demonstrate that CMIs reduce left atrial volume index (MD: -13.02, mL/m2 95% CI: -17.17 to -8.87, P<0.0001, I2 = 15.6%). However, the results do not show that CMIs improve late gadolinium enhancement (MD: 0.54 %, 95% CI: -0.48 to 1.56, P=0.2973, I2 = 0%). Similarly, there is no significant reduction in extracellular volume fraction (MD: 1.43 %, 95% CI: -0.02 to 2.88, P=0.0528, I2 = 0%).

CONCLUSION: CMIs have shown efficacy in improving cardiac structure in oHCM. However, the impact on myocardial fibrosis remains unclear.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Lu, Zhu, Tian, et al. Effect of cardiac myosin inhibitors on cardiac structure and myocardial fibrosis in obstructive hypertrophic cardiomyopathy: a meta-analysis of cardiac magnetic resonance outcomes. Clin Radiol. 2026. PMID: 42715826. doi:10.1016/j.crad.2026.107416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。